Innate immune responses to SARS-CoV-2 in the lung and blood of patients with severe COVID-19
Innate immune responses to SARS-CoV-2 in the lung and blood of patients with severe COVID-19
批准号:
10212766
负责人:
Eliver Ghosn
金额:
$35.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-24 至 2022-01-31
关键词:
2019-nCoVAdult Respiratory Distress SyndromeAffectAlveolarAlveolar MacrophagesAntibodiesAntibody titer measurementAntiviral AgentsAntiviral ResponseAspirate substanceBiological AssayBloodBlood specimenBone MarrowBronchoalveolar Lavage FluidCOVID-19CellsCessation of lifeCoronavirusCritical IllnessData SetDendritic CellsDevelopmentDiseaseDisease OutcomeExpression ProfilingFlow CytometryFollow-Up StudiesFundingGene ExpressionGene Expression ProfileGenesGrantHeterogeneityHumanIL8 geneImmuneImmunotherapyIndividualInfectionInfiltrationInflammationInflammatoryInflammatory ResponseInfluenzaInnate Immune ResponseInnate Immune SystemIntensive Care UnitsInterferon Type IInterferonsInvestigationKnowledgeLabelLeadLifeLigandsLungLymphoid CellMeasuresMembrane ProteinsMolecularMyelogenousMyeloid CellsNational Institute of Allergy and Infectious DiseaseNeutrophil InfiltrationOligonucleotidesOutcomePatientsPhenotypePlayPopulationPublic HealthRNA VirusesReportingResearchRoleSputumSymptomsT cell responseTissuesViralViral AntibodiesVirusVirus ReplicationYolk Sacbasecell typechemokinecytokine release syndromeeffective therapyendotrachealexperiencefetalhigh dimensionalityimmunopathologyinsightinterstitialmacrophagemonocytenovelnovel coronaviruspandemic diseaseprogenitorreceptorrecruitrespiratoryresponsesingle-cell RNA sequencingtargeted treatmenttreatment strategy
中文摘要
总结
英文摘要
SUMMARY
COVID-19 disease is an ongoing global pandemic caused by a new beta-coronavirus SARS-CoV-
2. A major obstacle to battling SARS-CoV-2 is a better understanding of the human innate immune
responses that can lead to an uncontrolled hyper-inflammation in the lung and, ultimately, to an
acute respiratory distress syndrome (ARDS) in some patients but not others. Due to the rapid
emergence of this pandemic, very limited knowledge is available on the lung-specific innate
immune responses to SARS-CoV-2 that could lead to ARDS (and in some cases death) or instead
elicit a protective antiviral response (e.g., type-I interferons, interferon-stimulated genes).
The role of the human innate immune system, particularly the myeloid cells, in initiating a “cytokine
storm” and generalized hyper-inflammation has been reported, but specifically how lung-resident
macrophages vs. infiltrating monocytes differentially respond to SARS-CoV-2 and how each
myeloid subset contribute to either protective antiviral responses or uncontrolled hyper-
inflammation and ARDS remain unknown. Hence, an in-depth study of the myeloid compartment
in the lung and blood of severe COVID-19 patients in ICU is critical to better understand the
initiation and persistence of ARDS and, most importantly, to the development of more efficient
and targeted therapy.
Our project’s primary objective is to resolve, at a single-cell level, the specific myeloid subsets,
including lung-resident alveolar and interstitial macrophages, dendritic cells, as well as infiltrating
blood monocytes, that are responsible for protective antiviral responses (e.g., type-I interferons,
interferon-stimulated genes) and/or aberrant hyper-inflammatory responses that lead to ARDS
(e.g., “cytokine storm”, neutrophil recruitment, etc.). Through these studies, we will develop novel
insights into the molecular programming and heterogeneity of the human innate immune
responses to SARS-CoV-2 infection and identify potential target genes to inform effective
treatment strategies.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes.
baritodinib减弱了由肺部膨胀单核细胞驱动的COVID-19的促炎阶段。
DOI:
10.1016/j.celrep.2022.110945
发表时间:
2022-06-14
期刊:
CELL REPORTS
影响因子:
8.8
作者:
[Dobosh, Brian, Zandi, Keivan, Giraldo, Diego Moncada, Goh, Shu Ling, Musall, Kathryn, Aldeco, Milagros, LeCher, Julia, Giacalone, Vincent D., Yang, Junkai, Eddins, Devon J., Bhasin, Manoj, Ghosn, Eliver, Sukhatme, Vikas, Schinazi, Raymond F., Tirouvanziam, Rabindra]
通讯作者:
Tirouvanziam, Rabindra
DOI:
10.4049/jimmunol.2100344
发表时间:
2021-12-15
期刊:
JOURNAL OF IMMUNOLOGY
影响因子:
4.4
作者:
[Eddins, Devon J., Kosters, Astrid, Waters, Jeffrey, Sosa, Jasmine, Phillips, Megan, Yadava, Koshika, Herzenberg, Leonore A., Kuipers, Hedwich F., Ghosn, Eliver Eid Bou]
通讯作者:
Ghosn, Eliver Eid Bou
flowBEAT: a multiparameter flow cytometry assay to discover longitudinal antibody responses associated with efficient recovery from COVID-19
-
批准号:10516078
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2021
-
负责人:Eliver Ghosn
-
依托单位:
flowBEAT: a multiparameter flow cytometry assay to discover longitudinal antibody responses associated with efficient recovery from COVID-19
-
批准号:10355136
-
项目类别:
-
资助金额:$23.22万
-
财政年份:2021
-
负责人:Eliver Ghosn
-
依托单位:
海外基金